Investigational drug · Phase 2
CID-103
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Immune Thrombocytopenia, Antibody Mediated Rejection.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "CID-103"
First trial start
2025
Jan 3, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CID-103", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Immune Thrombocytopenia
- Antibody Mediated Rejection
Approved drugs for the same conditions: Immune thrombocytopenia · Hematology and blood cancers · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "CID-103" as an intervention, largest first.
CASI pharmaceuticals, Inc.Industry
NCT07017725 · 75 participants (planned) · Start Jan 3, 2025 · Primary completion Jun 1, 2026
Drug: CID-103 · For: Chronic Immune Thrombocytopenia
Sites: Tangshan, China; Zhengzhou, China; Nanchang, China · 6 sites in all
CASI pharmaceuticals, Inc.Industry
NCT07641426 · 58 participants (planned) · Start Jun 9, 2026 · Primary completion May 2030
Drug: CID-103 · For: Antibody Mediated Rejection
Sites: Beijing, China; Guangzhou, China; Wuhan, China · 4 sites in all
- A Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune ThrombocytopeniaNot yet recruiting
CASI pharmaceuticals, Inc.Industry
NCT07946549 · 54 participants (planned) · Start Nov 30, 2026 · Primary completion Nov 30, 2028
Drug: CID-103 · For: Chronic Immune Thrombocytopenia
Sites: Beijing, China; Guangzhou, China; Tangshan, China · 11 sites in all
CASI pharmaceuticals, Inc.Industry
NCT04758767 · 10 participants · Start Mar 22, 2021 · Primary completion Jan 19, 2023
Drug: CID-103 · For: Multiple Myeloma
Sites: Nantes, France; Rennes, France; Villejuif, France · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Immune Thrombocytopenia
- Zola-celBMS-986353, CC-97540Phase 33 trials
Bristol Myers Squibb · Systemic Sclerosis, Lupus Erythematosus, Systemic, Lupus Nephritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.